OTC: EDTXF - Spectral Medical Inc.

Rentabilité sur six mois: -4.2%
Secteur: Healthcare

Calendrier des promotions Spectral Medical Inc.


À propos de l'entreprise

Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream.

plus de détails
It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

ISIN CA8475771033
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cad
Див.доход ао 57.14
Дивиденд ао 0.1641
Сайт https://spectraldx.com
Цена ао 0.423
Changement de prix par jour: -3.39% (0.354)
Changement de prix par semaine: +6.21% (0.322)
Changement de prix par mois: -16.59% (0.41)
Changement de prix sur 3 mois: -24% (0.45)
Changement de prix sur six mois: -4.2% (0.357)
Changement de prix par an: +6.88% (0.32)
Evolution du prix sur 3 ans: +62.09% (0.211)
Evolution du prix sur 5 ans: -24.22% (0.4513)
Evolution des prix sur 10 ans: 0% (0.342)
Evolution des prix depuis le début de l'année: -16.59% (0.41)

Sous-estimation

Nom Signification Grade
P/S 69.3 1
P/BV -6.69 0
P/E 0 0
EV/EBITDA -10.38 0
Total: 2.25

Efficacité

Nom Signification Grade
ROA, % -300.56 0
ROE, % 94.64 10
Total: 3.33

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0.5 5
Total: 2.35

Devoir

Nom Signification Grade
Debt/EBITDA -0.719 10
Total: 9.4

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -44.28 0
Rentabilité Ebitda, % 214.87 10
Rentabilité EPS, % 98.67 9
Total: 7.8

Établissements Volume Partager, %
Benedetti & Gucer, Inc. 22200 0.01



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Christopher Seto CEO, CFO & Director 351.22k
Dr. John A. Kellum M.D. Chief Medical Officer 325.75k

Adresse: Canada, Toronto, 135 The West Mall - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://spectraldx.com